Business unit Rx

_Marketing the new parenteral iron replacement product Ferinject^®.

_Developing and optimising partnerships with Roche and CellCept.

_Establishing subsidiaries in a number of markets to complement the network of first-class 
  licensing partners. This will create faster, more precise and more direct access to the needs
  of different markets and will strengthen the exchange of information and know-how on a
  global level.

_Significantly expanding the indication areas for Ferinject^®.

_Developing the phosphate binder PA21 and the new generation of iron replacement products.

_Researching and developing new products for treating iron deficiency diseases and anaemia.

_Expanding and developing networks with international opinion leaders.

_Expanding the portfolio of internationally marketed medicines by intensifying the search
  for licensed products and new products and by acquiring new companies.

Business unit Consumer Healthcare

_Ensuring continuity as regards product profitability, quality and reputation.

_Continuing to internationalise the product range.

_Developing the strategic alliance between Galenica pharmacies and Alliance Boots pharmacies.

_Developing the own range of products.

_Expanding the portfolio of internationally marketed medicines by intensifying the search
  for licensed products and new products and by acquiring new companies.